Xeris Pharmaceuticals Q3 2024 Earnings Preview
| XERS Stock | USD 3.45 0.27 8.49% |
Slightly above 55% of Xeris Pharmaceuticals' private investors are presently thinking to get in. The analysis of overall sentiment of trading Xeris Pharmaceuticals stock suggests that some investors are interested at this time. Xeris Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Xeris Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Xeris |
Xeris Pharmaceuticals set to announce Q3 earnings - Consensus EPS Estimate is -0.08 and Revenue Estimate is 51.43M .
Read at seekingalpha.com
 |
Xeris Pharmaceuticals Fundamental Analysis
We analyze Xeris Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xeris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xeris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Xeris Pharmaceuticals is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Xeris Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Xeris Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Xeris Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xeris Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Xeris Pharmaceuticals Related Equities
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| TERN | Terns Pharmaceuticals | 7.82 | ||||
| HOOK | Hookipa Pharma | 6.90 | ||||
| MREO | Mereo BioPharma | 4.71 | ||||
| MCRB | Seres Therapeutics | 4.55 | ||||
| CDTX | Cidara Therapeutics | 3.11 | ||||
| INZY | Inozyme Pharma | 2.64 | ||||
| PDSB | PDS Biotechnology | 1.90 | ||||
| DAWN | Day One | 1.33 | ||||
| PLX | Protalix Biotherapeutics | 0.60 | ||||
| IBRX | Immunitybio | 0.39 | ||||
| ELEV | Elevation Oncology | 1.59 | ||||
| HEPA | Hepion Pharmaceuticals | 4.48 |
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.